Targeting sTNF/TNFR1 signaling as a new therapeutic strategy

Antibodies

Volumn 4, Issue 1, 2015, Pages 48-70

  Fischer, Roman ^a   Kontermann, Roland E ^a   Maier, Olaf ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Antibodies; Autoimmune diseases; Inflammation; Neurodegeneration; TNF; TNF receptors

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LENERCEPT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALZHEIMER DISEASE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CROHN DISEASE; DRUG TARGETING; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE REGENERATION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ULCERATIVE COLITIS;

EID: 85106526513     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib4010048     Document Type: Review

References (124)

1. Aggarwal, B.B. Signalling pathways of the TNF superfamily: A double-edged sword. Nat. Rev. Immunol. 2003, 3, 745-756.
2. Locksley, R.M.; Killeen, N.; Lenardo, M.J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001, 104, 487-501.
3. Apostolaki, M.; Armaka, M.; Victoratos, P.; Kollias, G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr. Dir. Autoimmun. 2010, 11, 1-26.
4. Kollias, G. TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin. Arthritis Rheum. 2005, 34, 3-6.
5. Wajant, H.; Pfizenmaier, K.; Scheurich, P. Tumor necrosis factor signaling. Cell Death Diff. 2003, 10, 45-65.
6. Wong, M.; Ziring, D.; Korin, Y.; Desai, S.; Kim, S.; Lin, J.; Gjertson, D.; Braun, J.; Reed, E.; Singh, RR. TNFa blockade in human diseases: Mechanisms and future directions. Clin. Immunol. 2008, 126, 121-136.
7. Kontermann, R.E.; Scheurich, P.; Pfizenmaier, K. Antagonists of TNF action: Clinical experience and new developments. Exp. Opin. Drug Discov. 2009, 4, 279-292.
8. Tracey, D.; Klareskog, L.; Sasso, E.H.; Salfeld, J.G.; Tak, P.P. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 2008, 177, 244-279.
9. Cessak, G.; Kuzawihska, O.; Burda, A.; Lis, K.; Wojnar, M.; Mirowska-Guzel, D.; Bałkowiec-Iskra, E. TNF inhibitors-Mechanisms of action, approved and off-label indications. Pharmacol. Rep. 2014, 66, 836-844.
10. van Oosten, B.W.; Barkhof, F.; Truyen, L.; Boringa, J.B.; Bertelsmann, F.W.; von Blomberg, B.M.; Woody, J.N.; Hartung, HP.; Polman, C.H. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47, 1531-1534.
11. The Lenercept Study Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999, 53, 457-465.
12. Slifman, N.R.; Gershon, S.K.; Lee, J.H.; Edwards, E.T.; Braun, M.M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis actor alpha-neutralizing agents. Arthritis Rheum. 2003, 48, 319–324.
13. Sicotte, N.L.; Voskuhl R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001, 57, 1885–1888.
14. Shakoor, N.; Michalska, M.; Harris, C.A.; Block, J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002, 359, 579–580.
15. Brown, S.L.; Greene, M.H.; Gershon, S.K.; Edwards, E.T.; Braun, M.M. Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002, 46, 3151–3158.
16. Black, R.A.; Rauch, C.T.; Kozlosky, C.J.; Peschon, J.J.; Slack, J.L.; Wolfson, M.F.; Castner, B.J.; Stocking, K.L.; Reddy, P.; Srinivasan, S.; et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997, 385, 729–733.
17. Grell, M.; Douni, E.; Wajant, H.; Löhden, M.; Clauss, M.; Maxeiner, B.; Georgopoulos, S.; Lesslauer, W.; Kollias, G.; Pfizenmaier, K.; et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83, 793–802.
18. Wallach, D.; Engelmann, H.; Nophar, Y.; Aderka, D.; Kemper, O.; Hornik, V.; Holtmann, H.; Brakebusch, C. Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl. 1991, 35, 51–57.
19. Solomon, K.A.; Pesti, N.; Wu, G.; Newton, R.C. Cutting edge: A dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J. Immunol. 1999, 163, 4105–4108.
20. Aderka, D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996, 7, 231–240.
21. Tansey, M.G.; Szymkowski, D.E. The TNF superfamily in 2009: New pathways, new indications, and new drugs. Drug Discov. Today 2009, 14, 1082–1088.
22. Pfizenmaier, K.; Szymkowski, D.E. Workshop Summary: Introduction to rational design of new means for therapeutic modulation of function of the TNF family. Adv. Exp. Med. Biol. 2011, 691, 487–491.
23. van Hauwermeiren, F.; Vandenbroucke, R.E.; Libert, C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 2011, 22, 311–319.
24. Chan, F.K.; Chun, H.J.; Zheng, L.; Siegel, R.M.; Bui, K.L.; Lenardo, M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288, 2351–2354.
25. vanden Berghe, T.; Linkermann, A.; Jouan-Lanhouet, S.; Walczak, H.; Vandenabeele, P. Regulated necrosis: The expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 2014, 15, 135–147.
26. Walczak, H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol. Rev. 2011, 244, 9–28.
27. Wajant, H.; Scheurich, P. TNFR1-induced activation of the classical NF-κB pathway. FEBS J. 2011, 278, 862–876.
28. Kaltschmidt, B.; Baeuerle, P.A.; Kaltschmidt, C. Potential involvement of the transcription factor NF-kappa B in neurological disorders. Mol. Aspects Med. 1993, 14, 171–190.
29. Sabio, G.; Davis, R.J. TNF and MAP kinase signalling pathways. Semin. Immunol. 2014, 26, 237–245.
30. Guma, M.; Firestein, G.S. c-Jun N-Terminal Kinase in inflammation and rheumatic diseases. Open Rheumatol. J. 2012, 6, 220–231.
31. Yang, Y.; Kim, S.C.; Yu, T.; Yi, Y.S.; Rhee, M.H.; Sung, G.H.; Yoo, B.C.; Cho, J.Y. Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses. Mediators Inflamm. 2014, 352371.
32. Naudé, P.J.; den Boer, J.A.; Luiten, P.G.; Eisel, U.L. Tumor necrosis factor receptor cross-talk. FEBS J. 2011, 278, 888–898.
33. Rauert, H.; Wicovsky, A.; Müller, N.; Siegmund, D.; Spindler, V.; Waschke, J.; Kneitz, C.; Wajant, H. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J. Biol. Chem. 2010, 285, 7394–7404.
34. Fischer, R.; Maier, O.; Naumer, M.; Krippner-Heidenreich, A.; Scheurich, P.; Pfizenmaier, K. Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFκB pathway. Cell Signal. 2011, 23, 161–170.
35. Marchetti, L.; Klein, M.; Schlett, K.; Pfizenmaier, K.; Eisel, U.L. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J. Biol. Chem. 2004, 279, 32869–32881.
36. Dolga, A.M.; Nijholt, I.M.; Ostroveanu, A.; Ten Bosch, Q.; Luiten, P.G.; Eisel, U.L. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J. Alz. Dis. 2008, 13, 111–122.
37. Fischer, R.; Maier, O.; Siegemund, M.; Wajant, H.; Scheurich, P.; Pfizenmaier, K. A TNF Receptor 2 selective agonist rescues neurons from oxidative stress-induced cell death. PLoS One 2011, 6, e27621.
38. Fischer, R.; Wajant, H.; Kontermann, R.; Pfizenmaier, K.; Maier, O. Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor. Glia 2014, 62, 272–283.
39. Wilhelm, P.; Ritter, U.; Labbow, S.; Donhauser, N.; Rollinghoff, M.; Bogdan, C.; Korner, H. Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J. Immunol. 2001, 166, 4012–4019.
40. Pasparakis, M.; Alexopoulou, L.; Episkopou, V.; Kollias, G. Immune and inflammatory responses in TNFα-deficient mice: A critical requirement for TNFα in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 1996, 184, 1397–1411.
41. Mielke, M.E.; Peters, C.; Hahn, H. Cytokines in the induction and expression of T-cell-mediated granuloma formation and protection in the murine model of listeriosis. Immunol. Rev. 1997, 158, 79–93.
42. Mackay, F.; Loetscher, H.; Stueber, D.; Gehr, G.; Lesslauer, W. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J. Exp. Med. 1993, 177, 1277–1286.
43. Rothe, J.; Lesslauer, W.; Lötscher, H.; Lang, Y.; Koebel, P.; Köntgen, F.; Althage, A.; Zinkernagel, R.; Steinmetz, M.; Bluethmann, H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364, 798–802.
44. Rothe, J.; Mackay, F.; Bluethmann, H.; Zinkernagel, R.; Lesslauer, W. Phenotypic analysis of TNFR1-deficient mice and characterization of TNFR1-deficient fibroblasts in vitro. Circ. Shock 1994, 44, 51–56.
45. Xu, J.; Chakrabarti, A.K.; Tan, J.L.; Ge, L.; Gambotto, A.; Vujanovic, N.L. Essential role of the TNF–TNFR2 cognate interaction in mouse dendritic cell-natural killer cell crosstalk. Blood 2007, 109, 333–3341.
46. Musicki, K.; Briscoe, H.; Tran, S.M.; Britton, W.J.; Saunders, B.M. Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection. Infect. Immun. 2006, 74, 3180–3189.
47. Torres, D.; Janot, L.; Quesniaux, V.F.; Grivennikov, S.I.; Maillet, I.; Sedgwick, J.D.; Ryffel, B.; Erard, F. Membrane tumor necrosis factor confers partial protection to Listeria infection. Am. J. Pathol. 2005, 167, 1677–1687.
48. Sakaguchi, S. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 2000, 101, 455–458.
49. Sakaguchi, S.; Yamaguchi, T.; Nomura, T.; Ono, M. Regulatory T cells and immune tolerance. Cell 2008, 133, 775–787.
50. Chen, X.; Baumel, M.; Männel, D.N.; Howard, O.M.; Oppenheim, J.J. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J. Immunol. 2007, 179, 154–161.
51. Chen, X.; Subleski, J.J.; Kopf, H.; Howard, O.M.; Männel, D.N.; Oppenheim, J.J. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+ CD25+ FoxP3+ T regulatory cells: Applicability to tumor-infiltrating T regulatory cells. J. Immunol. 2008, 180, 6467–6471.
52. Chen, X.; Oppenheim, J.J. TNF-alpha: An activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr. Dir. Autoimmun. 2010, 11, 119–134.
53. Chen, X.; Wu, X.; Zhou, Q.; Howard, O.M.; Netea, M.G.; Oppenheim, J.J. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T cell phenotype in the inflammatory environment. J. Immunol. 2013, 190, 1076–1084.
54. Kim, J.M.; Rasmussen, J.P.; Rudensky, A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 2007, 8, 191–197.
55. Xanthoulea, S.; Pasparakis, M.; Kousteni, S.; Brakebusch, C.; Wallach, D.; Bauer, J.; Lassmann, H.; Kollias, G. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J. Exp. Med. 2004, 200, 367–376.
56. McDermott, M.F.; Aksentijevich, I.; Galon, J.; McDermott, E.M.; Ogunkolade, B.W.; Centola, M.; Mansfield, E.; Gadina, M.; Karenko, L.; Pettersson, T.; et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97, 133–144.
57. Kimberley, F.C.; Lobito, A.A.; Siegel, R.M.; Screaton, G.R. Falling into TRAPS—Receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res. Ther. 2007, 9, 217.
58. Bhatia, M. Acute pancreatitis as a model of SIRS. Front. Biosci. 2009, 14, 2042–2050.
59. Bhatia, M.; Moochhala, S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J. Path. 2004, 202, 145–156.
60. Kleinbongard, P.; Schulz, R.; Heusch, G. TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail. Rev. 2011, 16, 49–69.
61. Kontoyiannis, D.; Pasparakis, M.; Pizarro, T.T.; Cominelli, F.; Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies. Immunity 1999, 10, 387–398.
62. Piguet, P.F.; Grau, G.E.; Vesin, C.; Loetscher, H.; Gentz, R.; Lesslauer, W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992, 77, 510–514.
63. Mori, L.; Iselin, S.; De Libero, G.; Lesslauer, W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J. Immunol. 1996, 157, 3178–3182.
64. Dickson, D.W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 1997, 56, 321–339.
65. Mogi, M.; Harada, M.; Riederer, P.; Narabayashi, H.; Fujita, K.; Nagatsu, T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994, 165, 208–210.
66. Hofman, F.M.; Hinton, D.R.; Johnson, K.; Merrill, J.E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 1989, 170, 607–612.
67. Probert, L.; Akassoglou, K.; Pasparakis, M.; Kontogeorgos, G.; Kollias, G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA 1995, 92, 11294–11298.
68. Gregory, A.P.; Dendrou, C.A.; Attfield, K.E.; Haghikia, A.; Xifara, D.K.; Butter, F.; Poschmann, G.; Kaur, G.; Lambert, L.; Leach, O.A.; et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012, 488, 508–511.
69. Eugster, H.P.; Frei, K.; Bachmann, R.; Bluethmann, H.; Lassmann, H.; Fontana, A. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur. J. Immunol. 1999, 29, 626–632.
70. Suvannavejh, G.C.; Lee, H.O.; Padilla, J.; Dal Canto, M.C.; Barrett, T.A.; Miller, S.D. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell. Immunol. 2000, 205, 24–33.
71. Kassiotis, G.; Kollias, G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: Implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 2001, 193, 427–434.
72. Williams, S.K.; Maier, O.; Fischer, R.; Fairless, R.; Hochmeister, S.; Stojic, A.; Pick, L.; Haar, D.; Musiol, S.; Storch, M.K.; et al. Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS One 2014, 9, e90117.
73. Alexopoulou, L.; Kranidioti, K.; Xanthoulea, S.; Denis, M.; Kotanidou, A.; Douni, E.; Blackshear, P.J.; Kontoyiannis, D.L.; Kollias, G. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur. J. Immunol. 2006, 36, 2768–2780.
74. Palladino, M.A.; Bahjat, F.R.; Theodorakis, E.A.; Moldawer, L.L. Anti-TNF-α therapies: The next generation. Nat. Rev. Drug Discov. 2003, 2, 736–746.
75. Sedger, L.M.; McDermott, M.F. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants—Past, present and future. Cytokine Growth Factor Rev. 2014, 25, 453–472.
76. Monaco, C.; Nanchahal, J.; Taylor, P.; Feldmann, M. Anti-TNF therapy: Past, present and future. Int. Immunol. 2015, 27, 55–62.
77. Beck, A.; Reichert, J.M. Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry. MAbs 2013, 5, 621–623.
78. Christen, U.; Thuerkauf, R.; Stevens, R.; Lesslauer, W. Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Hum. Immunol. 1999, 60, 774–790.
79. Abraham, E.; Laterre, P.F.; Garbino, J.; Pingleton, S.; Butler, T.; Dugernier, T.; Margolis, B.; Kudsk, K.; Zimmerli, W.; Anderson, P.; et al. Lenercept (p55 tumor necrosis factor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit. Care Med. 2001, 29, 503–570.
80. Hayashi, T.; Faustman, D. NOD mice are defective in proteasome production and activation of NF-kappaB. Mol. Cell. Biol. 1999, 19, 8646–8659.
81. Faustman, D.; Davis, M. TNF receptor 2 pathway: Drug target for autoimmune diseases. Nat. Rev. Drug Discov. 2010, 9, 482–493.
82. Kodama, S.; Davis, M.; Faustman, D.L. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell. Mol. Life Sci. 2005, 62, 1850–1862.
83. Ban, L.; Zhang, J.; Wang, L.; Kuhtreiber, W.; Burger, D.; Faustman, D.L. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc. Natl. Acad. Sci. USA 2008, 105, 13644–13649.
84. Askenasy, N.; Kaminitz, A.; Yarkoni, S. Mechanisms of T regulatory cell function. Autoimmun. Rev. 2008, 7, 370–375.
85. Nagar, M.; Jacob-Hirsch, J.; Vernitsky, H.; Berkun, Y.; Ben-Horin, S.; Amariglio, N.; Bank, I.; Kloog, Y.; Rechavi, G.; Goldstein, I. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J. Immunol. 2010, 184, 3570–3581.
86. Annunziato, F.; Cosmi, L.; Liotta, F.; Lazzeri, E.; Manetti, R.; Vanini, V.; Romagnani, P.; Maggi, E.; Romagnani, S. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J. Exp. Med. 2002, 196, 379–387.
87. Fontaine, V.; Mohand-Said, S.; Hanoteau, N.; Fuchs, C.; Pfizenmaier, K.; Eisel, U. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J. Neurosci. 2002, 22, RC216.
88. Arnett, H.A.; Mason, J.; Marino, M.; Suzuki, K.; Matsushima, G.K.; Ting, J.P. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 2001, 4, 1116–1122.
89. Maier, O.; Fischer, R.; Agresti, C.; Pfizenmaier, K. TNFR2 activation protects oligodendrocyte progenitor cells against oxidative stress, Bioch. Biophys. Res. Comm. 2013, 440, 336–341.
90. Patel, J.R.; Williams, J.L.; Muccigrosso, M.M.; Liu, L.; Sun, T.; Rubin, J.B.; Klein, R.S. Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS. Acta Neuropathol. 2012, 124, 847–860.
91. Ruuls, S.R.; Hoek, R.M.; Ngo, V.N.; McNeil, T.; Lucian, L.A.; Janatpour, M.J.; Körner, H.; Scheerens, H.; Hessel, E.M.; Cyster, J.G.; et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001, 15, 533–543.
92. Saunders, B.M.; Tran, S.; Ruuls, S.; Sedgwick, J.D.; Briscoe, H.; Britton, W.J. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J. Immunol. 2005, 174, 4852–4859.
93. Fremond, C.; Allie, N.; Dambuza, I.; Grivennikov, S.I.; Yeremeev, V.; Quesniaux, V.F.; Jacobs, M.; Ryffel, B. Membrane TNF confers protection to acute mycobacterial infection. Respir. Res. 2005, 6, 136.
94. Kontermann, R.E.; Münkel, S.; Neumeyer, J.; Müller, D.; Branschädel, M.; Scheurich, P.; Pfizenmaier, K. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J. Immunother. 2008, 31, 225–234.
95. Steed, P.M.; Tansey, M.G.; Zalevsky, J.; Zhukovsky, E.A.; Desjarlais, J.R.; Szymkowski, D.E.; Abbott, C.; Carmichael, D.; Chan, C.; Cherry, L.; et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003, 301, 1895–1898.
96. Zalevsky, J.; Secher, T.; Ezhevsky, S.A.; Janot, L.; Steed, P.M.; O'Brien, C.; Eivazi, A.; Kung, J.; Nguyen, D.H.; Doberstein, S.K.; et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J. Immunol. 2007, 179, 1872–1883.
97. Olleros, M.L.; Vesin, D.; Fotio, A.L.; Santiago-Raber, M.L.; Tauzin, S.; Szymkowski, D.E.; Garcia, I. Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. J. Hepatol. 2010, 53, 1059–1068.
98. McCoy, M.K.; Martinez, T.N.; Ruhn, K.A.; Szymkowski, D.E.; Smith, C.G.; Botterman, B.R.; Tansey, K.E.; Tansey, M.G. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J. Neurosci. 2006, 26, 9365–9375.
99. McCoy, M.K.; Ruhn, K.A.; Martinez, T.N.; McAlpine, F.E.; Blesch, A.; Tansey, M.G. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in Hemiparkinsonian rats. Mol. Ther. 2008, 16, 1572–1579.
100. Taoufik, E.; Tseveleki, V.; Chu, S.Y.; Tselios, T.; Karin, M.; Lassmann, H.; Szymkowski, D.E.; Probert, L. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-κB. Brain 2011, 134, 2722–2735.
101. Brambilla, R.; Ashbaugh, J.J.; Magliozzi, R.; Dellarole, A.; Karmally, S.; Szymkowski, D.E.; Bethea, J.R. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain 2011, 134, 2736–2754.
102. Donnelly, D.J.; Popovich, P.G. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp. Neurol. 2008, 209, 378–388.
103. Gensel, J.C.; Zhang, B. Macrophage activation and its role in repair and pathology after spinal cord injury. Brain Res. 2015, in press.
104. Novrup, H.G.; Bracchi-Ricard, V.; Ellman, D.G.; Ricard, J.; Jain, A.; Runko, E.; Lyck, L.; Yli-Karjanmaa, M.; Szymkowski, D.E.; Pearse, D.D.; et al. Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. J. Neuroinflamm. 2014, 11, 159.
105. Clausen, B.; Degn, M.; Martin, N.; Couch, Y.; Karimi, L.; Ormhøj, M.; Mortensen, M.L.; Gredal, H.; Gardiner, C.; Sargent, I.I.; et al. Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. J. Neuroinflamm. 2014, 11, 203.
106. Shibata, H.; Yoshioka, Y.; Ohkawa, A.; Minowa, K.; Mukai, Y.; Abe, Y.; Taniai, M.; Nomura, T.; Kayamuro, H.; Nabeshi, H.; et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J. Biol. Chem. 2008, 283, 998–1007.
107. Shibata, H.; Yoshioka, Y.; Ohkawa, A.; Abe, Y.; Nomura, T.; Mukai, Y.; Nakagawa, S.; Taniai, M.; Ohta, T.; Mayumi, T., et al. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models. Cytokine 2008, 44, 229–233.
108. Shibata, H.; Yoshioka, Y.; Abe, Y.; Ohkawa, A.; Nomura, T.; Minowa, K.; Mukai, Y.; Nakagawa, S.; Taniai, M.; Ohta, T., et al. The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials 2009, 30, 6638–6647.
109. Nomura, T.; Abe, Y.; Kamada, H.; Shibata, H.; Kayamuro, H.; Inoue, M.; Kawara, T.; Arita, S.; Furuya, T.; Yamashita, T., et al. Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice. J. Control. Release 2011, 149, 8–14.
110. Kitagaki, M.; Isoda, K.; Kamada, H.; Kobayashi, T.; Tsunoda, S.; Tsutsumi, Y.; Niida, T.; Kujiraoka, T.; Ishigami, N.; Ishihara, M., et al. Novel TNFα receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice. J. Atheroscler. Thromb. 2012, 19, 36–46.
111. McCann, F.E.; Perocheau, D.P.; Ruspi, G.; Blazek, K.; Davies, M.L.; Feldmann, M.; Dean, J.L.; Stoop, A.A.; Williams, R.O. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol. 2014, 66, 2728–2738.
112. Steeland, S.; Puimège, L.; Vandenbroucke, R.E.; Van Hauwermeiren, F.; Haustraete, J.; Devoogdt, N.; Hulpiau, P.; Leroux-Roels, G.; Laukens, D.; Meuleman, P.; et al. Generation and characterization of small single domain antibodies inhibiting human TNF receptor 1. J. Biol. Chem. 2014, 290, 4022–4037.
113. Thoma, B.; Grell, M.; Pfizenmaier, K.; Scheurich, P. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J. Exp. Med. 1990, 172, 1019–1023.
114. Zettlitz, K.A.; Lorenz, V.; Landauer, K.H.; Münkel, S.; Herrmann, A.; Scheurich, P.; Pfizenmaier, K.; Kontermann, R.E. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs 2010, 2, 639–647.
115. Richter, F.; Liebig, T.; Guenzi, E.; Herrmann, A.; Scheurich, P.; Pfizenmaier, K.; Kontermann, R.E. Antagonistic TNF receptor one-specific antibody (ATROSAB): Receptor binding and in vitro bioactivity. PLoS One 2013, 8, e72156.
116. Sheehan, K.C.; Pinckard, J.K.; Arthur, C.D.; Dehner, L.P.; Goeddel, D.V.; Schreiber, R.D. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: Identification of a novel in vivo role for p75. J. Exp. Med. 1995, 181, 607–617.
117. Taoufik, E.; Petit, E.; Divoux, D.; Tseveleki, V.; Mengozzi, M.; Roberts, M.L.; Valable, S.; Ghezzi, P.; Quackenbush, J.; Brines, M.; et al. TNF receptor I sensitizes neurons to erythropoietin-and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc. Natl. Acad. Sci. USA 2008, 105, 6185–6190.
118. Ottoboni, L.; Frohlich, I.Y.; Lee, M.; Healy, B.C.; Keenan, B.T.; Xia, Z.; Chitnis, T.; Guttmann, C.R.; Khoury, S.J.; Weiner, H.L.; et al. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology 2013, 81, 1891–1899.
119. Ruddle, N.H.; Steinman, L. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int. Immunol. 1990, 2, 539–544.
120. Suen, W.E.; Bergman, C.M.; Hjelmström, P.; Ruddle, N.H. A critical role of lymphotoxin in experimental allergic encephalomyelitis. J. Exp. Med. 1997, 186, 1233–1240.
121. Chiang, E.Y.; Kolumam, G.A.; Yu, X.; Francesco, M.; Ivelja, S.; Peng, I.; Gribling, P.; Shu, J.; Lee, W.P.; Refino, C.J., et al. Targeted depletion of lymphotoxin-a-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat. Med. 2009, 15, 766–773.
122. Buch, M.H.; Conaghan, P.G.; Quinn, M.A.; Bingham, S.J.; Veale, D.; Emery, P. True infliximab resistance in rheumatoid arthritis: A role for lymphotoxin a? Ann. Rheum. Dis. 2004, 63, 1344–1346.
123. Calmon-Hamaty, F.; Combe, B.; Hahne, M.; Morel, J. Lymphotoxin a revisted: General features and implications in rheumatoid arthritis. Arthritis Res. 2011, 13, 232.
124. Okubo, Y.; Mera, T.; Wang, L.; Faustman, D.L. Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci. Rep. 2013, 3, 3153.